These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1762838)

  • 1. [The blood-brain barrier: implications for chemotherapy in brain tumors].
    Boaziz C; Breau JL; Morère JF; Israël L
    Pathol Biol (Paris); 1991 Oct; 39(8):789-95. PubMed ID: 1762838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
    Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
    Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Brain metastases of malignant melanomas].
    Boaziz C; Breau JL; Morere JF; Israël L
    Bull Cancer; 1991; 78(4):347-53. PubMed ID: 1859902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
    Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
    Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier and treatment of central nervous system tumors.
    Wiranowska M
    J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
    Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier and chemotherapeutic treatment of brain tumors.
    de Vries NA; Beijnen JH; Boogerd W; van Tellingen O
    Expert Rev Neurother; 2006 Aug; 6(8):1199-209. PubMed ID: 16893347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacologic bases of chemotherapy of brain tumors in children].
    Vassal G
    Bull Cancer; 1990; 77(7):699-713. PubMed ID: 2207360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors.
    Neuwelt EA; Rapoport SI
    Fed Proc; 1984 Feb; 43(2):214-9. PubMed ID: 6692941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of mustoforan in management of malignant glioma].
    Kobiakov GL
    Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
    [No Abstract]   [Full Text] [Related]  

  • 11. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy in the treatment of malignant brain tumors.
    Walker MD; Weiss HD
    Adv Neurol; 1975; 13():149-191. PubMed ID: 130061
    [No Abstract]   [Full Text] [Related]  

  • 13. [MCNU delivery into malignant brain tumor and normal brain tissue by intravenous or intraarterial infusion].
    Miyagami M; Tazoe M; Tsubokawa T
    Gan To Kagaku Ryoho; 1990 Feb; 17(2):275-80. PubMed ID: 2154161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
    Juillerat-Jeanneret L
    Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
    Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
    Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy delivery issues in central nervous system malignancy: a reality check.
    Muldoon LL; Soussain C; Jahnke K; Johanson C; Siegal T; Smith QR; Hall WA; Hynynen K; Senter PD; Peereboom DM; Neuwelt EA
    J Clin Oncol; 2007 Jun; 25(16):2295-305. PubMed ID: 17538176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats.
    Erdlenbruch B; Jendrossek V; Kugler W; Eibl H; Lakomek M
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):299-304. PubMed ID: 12357304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
    Cosolo W; Christophidis N
    Cancer Res; 1987 Dec; 47(23):6225-8. PubMed ID: 3119195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Burkitt's lymphoma involving the central nervous system.
    Ziegler JL; Magrath IT; Bluming AZ
    Afr J Med Med Sci; 1976 Jun; 5(2):121-4. PubMed ID: 829717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
    Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.